# US 2021/0231668 A1 · Kit and method for determining prostate cancer malignancy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0231668 A1
- Document ID: US20210231668A1
- Status: Published application
- Kind: A1
- Application number: 17/169,033
- Filed: 2021-02-05
- Published: 2021-07-29
- Earliest claimed: 2015-03-11
- Assignees: J-Pharma Co., Ltd.
- Applicants: J-Pharma Co., Ltd.
- Inventors: Nobuyuki Yanagisawa; Isao Okayasu
- Web page: https://patentgrep.com/patent/US20210231668A1

## CPC

- G01N 33/57555: of the prostate
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to kits and methods for determining (diagnosing) prostate cancer malignancy and to predict patient prognoses. Our findings suggested that elevated LAT1 expression in PC is a novel biomarker for high-grade malignancy. Independently of GS, aberrant LAT1 overexpression might be used to screen for aggressive phenotypes of PC that should be treated medically. Prostate biopsies are usually small samples, limiting the evaluation of the tumor area. Thus, LAT1 intensity in prostate biopsy samples may be more a reliable prognostic marker of LP. Especially, we propose LAT1 evaluation against PC with low-risk patients in order to screen who can receive active surveillance. Several LAT1 inhibitors have been found to suppress cancer cell proliferation, so inhibition of LAT1 may be a potential therapeutic strategy for PC and other human cancers.

## Claims

### Claim 1

A method for determining prostate cancer malignancy, comprising:
applying an anti-human LAT1 monoclonal antibody to a specimen tissue of prostate cancer from a patient classified as Gleason score <7 or Low according to D'Amico Risk Category;
performing immunohistochemical staining on the specimen tissue to determine the LAT1 score and/or intensity; and
determining whether the prostate cancer of the patient is in stable disease or local progression based on the score and/or intensity.

### Claim 2 (depends on 1)

The method for determining prostate cancer malignancy according to claim 1, wherein the monoclonal antibody recognizes human LAT1 amino acid residues specifically at positions 1 to 52 from the N-terminus.

### Claim 3 (depends on 1)

A method to clinically differentiate prostate cancer severity via application of LAT1 molecular target therapeutic agent(s), comprising:
determining malignancy of prostate cancer according to the method as claimed in claim 1; and
determining whether a therapeutic agent for prostate cancer is to be administered or not, based on the determination result.

### Claim 4 (depends on 2)

A method to clinically differentiate prostate cancer severity via application of LAT1 molecular target therapeutic agent(s), comprising:
determining malignancy of prostate cancer according to the method as claimed in claim 2; and
determining whether a therapeutic agent for prostate cancer is to be administered or not, based on the determination result.
